Jefferies Financial Group Comments on Vaxxinity, Inc.’s Q3 2022 Earnings (NASDAQ:VAXX)

Vaxxinity, Inc. (NASDAQ:VAXXGet Rating) – Investment analysts at Jefferies Financial Group raised their Q3 2022 earnings per share estimates for shares of Vaxxinity in a research note issued to investors on Tuesday, May 10th. Jefferies Financial Group analyst R. Song now anticipates that the company will post earnings of ($0.15) per share for the quarter, up from their previous estimate of ($0.32). Jefferies Financial Group also issued estimates for Vaxxinity’s Q4 2022 earnings at ($0.07) EPS, FY2022 earnings at ($0.50) EPS, FY2023 earnings at ($0.58) EPS, FY2024 earnings at ($0.52) EPS, FY2025 earnings at ($0.46) EPS and FY2026 earnings at ($0.46) EPS.

Vaxxinity (NASDAQ:VAXXGet Rating) last released its quarterly earnings results on Thursday, March 24th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.13).

A number of other equities analysts also recently weighed in on VAXX. Zacks Investment Research downgraded shares of Vaxxinity from a “hold” rating to a “sell” rating in a research note on Thursday, April 7th. Evercore ISI initiated coverage on shares of Vaxxinity in a research report on Wednesday, April 27th. They issued an “in-line” rating for the company.

VAXX opened at $4.37 on Friday. Vaxxinity has a 1-year low of $3.04 and a 1-year high of $22.77. The business has a 50 day moving average price of $4.29. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.46 and a quick ratio of 5.61.

Hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. bought a new stake in Vaxxinity during the fourth quarter valued at approximately $1,240,000. Millennium Management LLC purchased a new position in Vaxxinity during the 4th quarter valued at $489,000. Geode Capital Management LLC purchased a new position in Vaxxinity during the 4th quarter valued at $382,000. Virtu Financial LLC bought a new stake in shares of Vaxxinity during the 4th quarter valued at $93,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of Vaxxinity during the 4th quarter valued at $5,619,000. Institutional investors own 15.82% of the company’s stock.

In other news, major shareholder United Biomedical Inc acquired 18,105 shares of the firm’s stock in a transaction dated Tuesday, April 26th. The stock was bought at an average cost of $3.45 per share, for a total transaction of $62,462.25. Following the completion of the transaction, the insider now directly owns 51,611,559 shares in the company, valued at approximately $178,059,878.55. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mei Mei Hu bought 8,038 shares of the business’s stock in a transaction that occurred on Monday, April 25th. The shares were bought at an average cost of $3.37 per share, for a total transaction of $27,088.06. Following the completion of the purchase, the insider now owns 51,593,454 shares of the company’s stock, valued at $173,869,939.98. The disclosure for this purchase can be found here. Insiders have purchased a total of 30,950 shares of company stock valued at $106,759 in the last ninety days.

Vaxxinity Company Profile (Get Rating)

Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD.

Featured Stories

Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.